430 related articles for article (PubMed ID: 25191754)
1. The GIP receptor displays higher basal activity than the GLP-1 receptor but does not recruit GRK2 or arrestin3 effectively.
Al-Sabah S; Al-Fulaij M; Shaaban G; Ahmed HA; Mann RJ; Donnelly D; Bünemann M; Krasel C
PLoS One; 2014; 9(9):e106890. PubMed ID: 25191754
[TBL] [Abstract][Full Text] [Related]
2. A Dual GLP-1/GIP Receptor Agonist Does Not Antagonize Glucagon at Its Receptor but May Act as a Biased Agonist at the GLP-1 Receptor.
Al-Zamel N; Al-Sabah S; Luqmani Y; Adi L; Chacko S; Schneider TD; Krasel C
Int J Mol Sci; 2019 Jul; 20(14):. PubMed ID: 31330984
[TBL] [Abstract][Full Text] [Related]
3. Differential effects of glucose-dependent insulinotropic polypeptide receptor/glucagon-like peptide-1 receptor heteromerization on cell signaling when expressed in HEK-293 cells.
Al-Zaid B; Chacko S; Ezeamuzie CI; Bünemann M; Krasel C; Karimian T; Lanzerstorfer P; Al-Sabah S
Pharmacol Res Perspect; 2022 Oct; 10(5):e01013. PubMed ID: 36177761
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological characterization of mono-, dual- and tri-peptidic agonists at GIP and GLP-1 receptors.
Yuliantie E; Darbalaei S; Dai A; Zhao P; Yang D; Sexton PM; Wang MW; Wootten D
Biochem Pharmacol; 2020 Jul; 177():114001. PubMed ID: 32360365
[TBL] [Abstract][Full Text] [Related]
5. Genetic and biased agonist-mediated reductions in β-arrestin recruitment prolong cAMP signaling at glucagon family receptors.
Jones B; McGlone ER; Fang Z; Pickford P; Corrêa IR; Oishi A; Jockers R; Inoue A; Kumar S; Görlitz F; Dunsby C; French PMW; Rutter GA; Tan T; Tomas A; Bloom SR
J Biol Chem; 2021; 296():100133. PubMed ID: 33268378
[TBL] [Abstract][Full Text] [Related]
6. GLP-1 and GIP receptor signaling in beta cells - A review of receptor interactions and co-stimulation.
Mayendraraj A; Rosenkilde MM; Gasbjerg LS
Peptides; 2022 May; 151():170749. PubMed ID: 35065096
[TBL] [Abstract][Full Text] [Related]
7. Human epicardial adipose tissue expresses glucose-dependent insulinotropic polypeptide, glucagon, and glucagon-like peptide-1 receptors as potential targets of pleiotropic therapies.
Malavazos AE; Iacobellis G; Dozio E; Basilico S; Di Vincenzo A; Dubini C; Menicanti L; Vianello E; Meregalli C; Ruocco C; Ragni M; Secchi F; Spagnolo P; Castelvecchio S; Morricone L; Buscemi S; Giordano A; Goldberger JJ; Carruba M; Cinti S; Corsi Romanelli MM; Nisoli E
Eur J Prev Cardiol; 2023 Jun; 30(8):680-693. PubMed ID: 36799940
[TBL] [Abstract][Full Text] [Related]
8. Loss of GIPR in LEPR cells impairs glucose control by GIP and GIP:GLP-1 co-agonism without affecting body weight and food intake in mice.
Akindehin S; Liskiewicz A; Liskiewicz D; Bernecker M; Garcia-Caceres C; Drucker DJ; Finan B; Grandl G; Gutgesell R; Hofmann SM; Khalil A; Liu X; Cota P; Bakhti M; Czarnecki O; Bastidas-Ponce A; Lickert H; Kang L; Maity G; Novikoff A; Parlee S; Pathak E; Schriever SC; Sterr M; Ussar S; Zhang Q; DiMarchi R; Tschöp MH; Pfluger PT; Douros JD; Müller TD
Mol Metab; 2024 May; 83():101915. PubMed ID: 38492844
[TBL] [Abstract][Full Text] [Related]
9. Discovery of a potent GIPR peptide antagonist that is effective in rodent and human systems.
Yang B; Gelfanov VM; El K; Chen A; Rohlfs R; DuBois B; Kruse Hansen AM; Perez-Tilve D; Knerr PJ; D'Alessio D; Campbell JE; Douros JD; Finan B
Mol Metab; 2022 Dec; 66():101638. PubMed ID: 36400403
[TBL] [Abstract][Full Text] [Related]
10. Diabetes and obesity treatment based on dual incretin receptor activation: 'twincretins'.
Skow MA; Bergmann NC; Knop FK
Diabetes Obes Metab; 2016 Sep; 18(9):847-54. PubMed ID: 27160961
[TBL] [Abstract][Full Text] [Related]
11. Pharmacological characterization of human incretin receptor missense variants.
Fortin JP; Schroeder JC; Zhu Y; Beinborn M; Kopin AS
J Pharmacol Exp Ther; 2010 Jan; 332(1):274-80. PubMed ID: 19841474
[TBL] [Abstract][Full Text] [Related]
12. Body weight lowering effect of glucose-dependent insulinotropic polypeptide and glucagon-like peptide receptor agonists is more efficient in RAMP1/3 KO than in WT mice.
Leuthardt AS; Boyle CN; Raun K; Lutz TA; John LM; Le Foll C
Eur J Pharmacol; 2023 Sep; 955():175912. PubMed ID: 37454968
[TBL] [Abstract][Full Text] [Related]
13. Signaling profiles in HEK 293T cells co-expressing GLP-1 and GIP receptors.
Wang YZ; Yang DH; Wang MW
Acta Pharmacol Sin; 2022 Jun; 43(6):1453-1460. PubMed ID: 34446852
[TBL] [Abstract][Full Text] [Related]
14. Functional consequences of glucagon-like peptide-1 receptor cross-talk and trafficking.
Roed SN; Nøhr AC; Wismann P; Iversen H; Bräuner-Osborne H; Knudsen SM; Waldhoer M
J Biol Chem; 2015 Jan; 290(2):1233-43. PubMed ID: 25451942
[TBL] [Abstract][Full Text] [Related]
15. Differential importance of glucose-dependent insulinotropic polypeptide vs glucagon-like peptide 1 receptor signaling for beta cell survival in mice.
Maida A; Hansotia T; Longuet C; Seino Y; Drucker DJ
Gastroenterology; 2009 Dec; 137(6):2146-57. PubMed ID: 19766644
[TBL] [Abstract][Full Text] [Related]
16. Optimized GIP analogs promote body weight lowering in mice through GIPR agonism not antagonism.
Mroz PA; Finan B; Gelfanov V; Yang B; Tschöp MH; DiMarchi RD; Perez-Tilve D
Mol Metab; 2019 Feb; 20():51-62. PubMed ID: 30578168
[TBL] [Abstract][Full Text] [Related]
17. Regulation of energy metabolism through central GIPR signaling.
Liskiewicz A; Müller TD
Peptides; 2024 Jun; 176():171198. PubMed ID: 38527521
[TBL] [Abstract][Full Text] [Related]
18. Enhanced Endosomal Signaling and Desensitization of GLP-1R vs GIPR in Pancreatic Beta Cells.
Manchanda Y; Bitsi S; Chen S; Broichhagen J; Bernardino de la Serna J; Jones B; Tomas A
Endocrinology; 2023 Mar; 164(5):. PubMed ID: 36774542
[TBL] [Abstract][Full Text] [Related]
19. Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms.
Campbell JE
Mol Metab; 2021 Apr; 46():101139. PubMed ID: 33290902
[TBL] [Abstract][Full Text] [Related]
20. Structural determinants of dual incretin receptor agonism by tirzepatide.
Sun B; Willard FS; Feng D; Alsina-Fernandez J; Chen Q; Vieth M; Ho JD; Showalter AD; Stutsman C; Ding L; Suter TM; Dunbar JD; Carpenter JW; Mohammed FA; Aihara E; Brown RA; Bueno AB; Emmerson PJ; Moyers JS; Kobilka TS; Coghlan MP; Kobilka BK; Sloop KW
Proc Natl Acad Sci U S A; 2022 Mar; 119(13):e2116506119. PubMed ID: 35333651
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]